INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.
Publication
, Conference
Mellinghoff, IK; Van den Bent, MJ; Clarke, JL; Maher, EA; Peters, KB; Touat, M; De Groot, JF; De La Fuente, MI; Arrillaga-Romany, I; Wick, W ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2020
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2020
Volume
38
Issue
15
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Mellinghoff, I. K., Van den Bent, M. J., Clarke, J. L., Maher, E. A., Peters, K. B., Touat, M., … Cloughesy, T. F. (2020). INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).
Mellinghoff, Ingo K., Martin J. Van den Bent, Jennifer Leigh Clarke, Elizabeth Anne Maher, Katherine B. Peters, Mehdi Touat, John Frederick De Groot, et al. “INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.
Mellinghoff IK, Van den Bent MJ, Clarke JL, Maher EA, Peters KB, Touat M, et al. INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation. In: JOURNAL OF CLINICAL ONCOLOGY. 2020.
Mellinghoff, Ingo K., et al. “INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.
Mellinghoff IK, Van den Bent MJ, Clarke JL, Maher EA, Peters KB, Touat M, De Groot JF, De La Fuente MI, Arrillaga-Romany I, Wick W, Ellingson BM, Schoenfeld S, Tai F, Le K, Lu M, Steelman L, Hassan I, Pandya SS, Wen PY, Cloughesy TF. INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation. JOURNAL OF CLINICAL ONCOLOGY. 2020.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2020
Volume
38
Issue
15
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences